111 related articles for article (PubMed ID: 11557918)
1. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.
Thijssen HH; Drittij MJ; Vervoort LM; de Vries-Hanje JC
Clin Pharmacol Ther; 2001 Sep; 70(3):292-8. PubMed ID: 11557918
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
Thijssen HH; Flinois JP; Beaune PH
Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154
[TBL] [Abstract][Full Text] [Related]
3. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
4. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.
Takahashi H; Sato T; Shimoyama Y; Shioda N; Shimizu T; Kubo S; Tamura N; Tainaka H; Yasumori T; Echizen H
Clin Pharmacol Ther; 1999 Dec; 66(6):569-81. PubMed ID: 10613612
[TBL] [Abstract][Full Text] [Related]
6. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
[TBL] [Abstract][Full Text] [Related]
8. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H
Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
10. Genetic association between sensitivity to warfarin and expression of CYP2C9*3.
Steward DJ; Haining RL; Henne KR; Davis G; Rushmore TH; Trager WF; Rettie AE
Pharmacogenetics; 1997 Oct; 7(5):361-7. PubMed ID: 9352571
[TBL] [Abstract][Full Text] [Related]
11. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
[TBL] [Abstract][Full Text] [Related]
12. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.
Black DJ; Kunze KL; Wienkers LC; Gidal BE; Seaton TL; McDonnell ND; Evans JS; Bauwens JE; Trager WF
Drug Metab Dispos; 1996 Apr; 24(4):422-8. PubMed ID: 8801057
[TBL] [Abstract][Full Text] [Related]
13. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M
Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071
[TBL] [Abstract][Full Text] [Related]
14. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
[TBL] [Abstract][Full Text] [Related]
15. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.
Verstuyft C; Morin S; Robert A; Loriot MA; Beaune P; Jaillon P; Becquemont L
Pharmacogenetics; 2001 Nov; 11(8):735-7. PubMed ID: 11692083
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of warfarin elimination and its clinical implications.
Takahashi H; Echizen H
Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
[TBL] [Abstract][Full Text] [Related]
17. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
[TBL] [Abstract][Full Text] [Related]
18. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
Kim JS; Nafziger AN; Gaedigk A; Dickmann LJ; Rettie AE; Bertino JS
J Clin Pharmacol; 2001 Jul; 41(7):715-22. PubMed ID: 11452703
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
Yasar U; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML
Clin Pharmacol Ther; 2002 Jan; 71(1):89-98. PubMed ID: 11823761
[TBL] [Abstract][Full Text] [Related]
20. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]